Tango Therapeutics (TNGX) Competitors $9.25 +0.55 (+6.32%) As of 02:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNGX vs. VKTX, AMRX, CNTA, XENE, CGON, QURE, RARE, APLS, IMVT, and GMTXShould you be buying Tango Therapeutics stock or one of its competitors? The main competitors of Tango Therapeutics include Viking Therapeutics (VKTX), Amneal Pharmaceuticals (AMRX), Centessa Pharmaceuticals (CNTA), Xenon Pharmaceuticals (XENE), CG Oncology (CGON), uniQure (QURE), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), Immunovant (IMVT), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry. Tango Therapeutics vs. Its Competitors Viking Therapeutics Amneal Pharmaceuticals Centessa Pharmaceuticals Xenon Pharmaceuticals CG Oncology uniQure Ultragenyx Pharmaceutical Apellis Pharmaceuticals Immunovant Gemini Therapeutics Viking Therapeutics (NASDAQ:VKTX) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends. Does the media prefer VKTX or TNGX? In the previous week, Viking Therapeutics had 8 more articles in the media than Tango Therapeutics. MarketBeat recorded 14 mentions for Viking Therapeutics and 6 mentions for Tango Therapeutics. Viking Therapeutics' average media sentiment score of 0.69 beat Tango Therapeutics' score of 0.64 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, VKTX or TNGX? Viking Therapeutics has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. Which has higher valuation & earnings, VKTX or TNGX? Viking Therapeutics has higher earnings, but lower revenue than Tango Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViking TherapeuticsN/AN/A-$109.96M-$1.53-23.05Tango Therapeutics$24.30M42.30-$130.30M-$1.33-6.95 Is VKTX or TNGX more profitable? Viking Therapeutics has a net margin of 0.00% compared to Tango Therapeutics' net margin of -599.11%. Viking Therapeutics' return on equity of -19.98% beat Tango Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viking TherapeuticsN/A -19.98% -19.38% Tango Therapeutics -599.11%-79.72%-49.30% Do analysts rate VKTX or TNGX? Viking Therapeutics presently has a consensus target price of $86.42, suggesting a potential upside of 144.99%. Tango Therapeutics has a consensus target price of $10.50, suggesting a potential upside of 13.67%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Tango Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viking Therapeutics 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.86Tango Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do institutionals & insiders have more ownership in VKTX or TNGX? 76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 4.1% of Viking Therapeutics shares are held by insiders. Comparatively, 7.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryViking Therapeutics beats Tango Therapeutics on 10 of the 16 factors compared between the two stocks. Get Tango Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNGX vs. The Competition Export to ExcelMetricTango TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.02B$3.39B$6.03B$10.49BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-6.8622.8984.8927.32Price / Sales42.30268.54516.27196.49Price / CashN/A46.9537.5761.53Price / Book4.9710.4912.396.78Net Income-$130.30M-$52.58M$3.32B$276.59M7 Day Performance33.68%0.05%0.22%-0.21%1 Month Performance35.44%14.86%9.87%7.65%1 Year Performance33.68%17.29%75.52%33.95% Tango Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNGXTango Therapeutics1.6175 of 5 stars$9.25+6.3%$10.50+13.5%+27.2%$1.03B$24.30M-6.9590VKTXViking Therapeutics3.9714 of 5 stars$32.28+8.6%$86.42+167.7%-49.8%$3.34BN/A-21.1020Upcoming EarningsAMRXAmneal Pharmaceuticals3.222 of 5 stars$10.55+1.5%$12.00+13.7%+12.2%$3.26B$2.85B1,056.068,100CNTACentessa Pharmaceuticals2.8365 of 5 stars$23.00-1.0%$32.38+40.8%+34.5%$3.11B$6.85M-12.85200XENEXenon Pharmaceuticals2.4884 of 5 stars$39.55-0.2%$53.30+34.8%-2.8%$3.05B$7.50M-11.14210Analyst ForecastCGONCG Oncology2.1802 of 5 stars$38.13-4.2%$56.55+48.3%+14.2%$3.04B$1.14M-21.5461QUREuniQure3.4531 of 5 stars$52.91-3.7%$71.75+35.6%+945.4%$3.01B$27.12M-13.50500RAREUltragenyx Pharmaceutical4.3635 of 5 stars$30.19-3.3%$81.50+170.0%-43.6%$3.01B$610.16M-5.461,294News CoverageInsider TradeAnalyst RevisionAPLSApellis Pharmaceuticals4.1963 of 5 stars$24.36+2.4%$33.29+36.7%-15.4%$3.01B$754.65M-13.38770Analyst ForecastAnalyst RevisionIMVTImmunovant2.1366 of 5 stars$16.55-2.1%$33.20+100.6%-40.6%$2.95BN/A-5.81120News CoverageAnalyst ForecastGMTXGemini TherapeuticsN/A$67.78+2.9%N/A+50.7%$2.94BN/A-67.7830 Related Companies and Tools Related Companies VKTX Competitors AMRX Competitors CNTA Competitors XENE Competitors CGON Competitors QURE Competitors RARE Competitors APLS Competitors IMVT Competitors GMTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNGX) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tango Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
